May 1, 2021

Featuring an interview with Dr Morie A Gertz, including the following topics:

• Recent advances in the treatment of amyloid light chain (AL) amyloidosis (0:00)
• Case: A woman in her late 70s receiving medical care for monoclonal gammopathy of undetermined significance (MGUS) is diagnosed with AL amyloidosis (22:12)
• Case: A man in his late 70s being monitored for multiple myeloma after a diagnosis of smoldering multiple myeloma is found to have AL amyloidosis (25:04)
• Case: A man in his early 70s with amyloidosis with peripheral neuropathy receives a misdiagnosis of MGUS (26:29)
• Pathophysiology and diagnosis of AL amyloidosis (28:32)
• Case: A woman in her late 70s being monitored for MGUS is found to have AL amyloidosis (34:37)
• Design, eligibility criteria and key endpoints of the Phase III ANDROMEDA study evaluating subcutaneous daratumumab in combination with CyBorD versus CyBorD alone for patients with newly diagnosed AL amyloidosis (39:22)
• Activity and tolerability of pomalidomide, venetoclax or isatuximab in patients with AL amyloidosis (47:48)
• Mechanism of action and efficacy of CAEL-101, an antibody targeting light chain amyloid fibrils, for AL amyloidosis (53:48)
• Selection and sequencing of therapy for patients with AL amyloidosis (56:17)

CME information and select publications